VIS 649

Drug Profile

VIS 649

Alternative Names: VIS649

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Visterra
  • Developer Juntendo University; Visterra
  • Class Monoclonal antibodies
  • Mechanism of Action B-cell maturation antigen modulators; Immunomodulators; Transmembrane activator and CAML interactor protein modulators; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical IgA nephropathy

Most Recent Events

  • 31 Oct 2017 Preclinical trials in IgA nephropathy in Japan (Parenteral) before October 2017
  • 05 Oct 2017 VIS 649 is available for licensing as of 05 Oct 2017.
  • 31 Mar 2017 Visterra plans a phase I trial for IgA nephropathy in USA in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top